Lead-asset concentration
The company is substantially dependent on OKI-219, so setbacks would materially harm the business.
- Scope
- OKI-219
- Materiality
- high
OnKure Therapeutics, Inc.
OnKure Therapeutics, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing precision medicines for cancers and other diseases. Its pipeline centers on small-molecule drug candidates designed with structure-based drug design to selectively target mutated forms of biologically validated proteins, including PI3Kα.
10.28
10.28
| % | |
|---|---|
| Clinical-stage drug candidates | 100% Investigational small-molecule therapies being advanced through preclinical and clinical development. |
| PI3Kα-targeted programs | 0% Programs designed to selectively inhibit mutated PI3Kα drivers in cancer and related diseases. |
| Drug discovery platform | 0% Structure-based discovery capabilities using medicinal chemistry, x-ray crystallography, and computation. |
OnKure does not sell commercial products today; its near-term counterparties are research sites, CROs, manufacturers,...
- Clinical research organizations and trial sitesprimary
They support the development of OKI-219 and future programs by running studies and generating clinical data.
- Regulatory authoritiesprimary
They review clinical, manufacturing, and safety data needed for marketing approval.
- Manufacturing and supply partnersprimary
They provide drug substance, finished product, packaging, and scale-up support for development and launch.
- Potential future patients and physiciansemerging
They would use approved therapies for cancers and other diseases driven by specific mutations.
- Third-party payorsemerging
They determine coverage and reimbursement that would affect adoption of any approved product.
OnKure is incorporated in Delaware and has its principal executive offices in Boulder, Colorado...
- •Headquartered in Boulder, Colorado
- •Incorporated in Delaware
- •Clinical and regulatory activity is centered in the United States
- •Future patent protection and commercialization may extend internationally
- •Facilities are leased rather than owned
OnKure’s strategy is to advance a focused pipeline of precision medicines built around mutated PI3Kα and related...
01
Advance OKI-219 through clinical developmentshort-term
The company is substantially dependent on this lead program for value creation.
02
Develop additional product candidatesmedium-term
A broader pipeline reduces single-asset dependence and expands long-term optionality.
03
Establish manufacturing and commercialization readinessmedium-term
Biopharma value depends on scalable supply, launch capability, and market access if approved.
OnKure faces the typical risks of a clinical-stage biotech: no approved products, no product revenue, and heavy...
Clinical development failure
Drug candidates can fail to demonstrate efficacy, safety, or tolerability in trials.
- Scope
- Clinical-stage pipeline
- Materiality
- high
Regulatory approval risk
Approval depends on successful trial results, manufacturing readiness, and agency review.
- Scope
- FDA and other regulators
- Materiality
- high
Financing risk
The company expects to need additional capital to fund operations and development.
- Scope
- Equity, debt, collaborations
- Materiality
- high
Commercialization and reimbursement risk
Even approved therapies may face coverage, pricing, and adoption barriers.
- Scope
- Payors, physicians, patients
- Materiality
- medium
Research and development expense
Major driver of operating loss
Lease accounting
Occupancy and balance sheet presentation
Fair value of financing instruments
Financing gains/losses and dilution analysis
Stock-based compensation
Operating expense and dilution
: 29.4.2026